Officer Dennis Mulroy Files to Sell Another $1.15M in Stock, Continuing Recent Distribution
ANAB has more than doubled off its 52-week low of $11.402.
Summary
AnaptysBio officer Dennis Mulroy has filed to sell an additional $1.15 million in company stock, extending a recent trend of significant insider distribution despite the company's recent share repurchase announcement.
Key Events · Ownership and Investor Activity · ANAB
-
Officer Files to Sell $1.15M in Stock
Dennis Mulroy, an officer, filed a Form 144 to sell 22,491 shares of common stock, valued at approximately $1.15 million. The shares were acquired through a stock option exercise on the same day.
-
Continuation of Significant Insider Selling
This filing extends a pattern of substantial sales by Mulroy, who has sold 158,422 shares totaling over $8.8 million in gross proceeds over the past three months, as indicated in the filing's history.
-
Conflicting Signal with Share Repurchase Program
The ongoing insider selling occurs after AnaptysBio announced a new $100 million share repurchase program on May 12, 2026, creating a conflicting signal regarding management's view of the stock's value.
Analysis · ANAB · Life Sciences
Dennis Mulroy, an officer at AnaptysBio, has filed a Form 144 indicating intent to sell an additional $1.15 million worth of common stock. This follows a pattern of significant sales by Mulroy, totaling over $8.8 million in the past three months, and comes shortly after the company announced a $100 million share repurchase program. The consistent selling by a key officer, particularly after exercising options, suggests a lack of conviction at current price levels and contrasts with the company's stated intent to buy back shares.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANAB was trading at $50.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $11.40 to $72.36. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.